Gilead Q2 2026 Revenue Up 10% to $7.8B; Diluted Loss Per Share $(8.45) on $11.2B IPR&D Charges

GILEAD SCIENCES, INC.

Total Q2 2026 revenues increased 10% to $7.8 billion compared to Q2 2025.
Product sales excluding Veklury increased 10% to $7.6 billion, driven by HIV portfolio, Trodelvy, and Livdelzi.
Diluted loss per share was $(8.45) due to $11.2 billion in acquired IPR&D expenses from Arcellx, Tubulis, and Ouro Medicines acquisitions.
Biktarvy sales increased 7% to $3.8 billion; Descovy sales up 48% to $967 million.
Gilead updated 2026 guidance: product sales ex-Veklury now $29.8B-$30.1B, up from prior $29.4B-$29.8B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.